{
  "id": "55033064e9bde69634000036",
  "type": "summary",
  "question": "What is  the clinical value of naltrexone in Parkinson's disease patients?",
  "ideal_answer": "Naltrexone does not improve clinical features, including motor function, in Parkinson's disease patients. Naltrexone was shown to be effective for treatment of pathological gambling in Parkinson's disease patients.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/152622",
    "http://www.ncbi.nlm.nih.gov/pubmed/11254789",
    "http://www.ncbi.nlm.nih.gov/pubmed/22426027",
    "http://www.ncbi.nlm.nih.gov/pubmed/7969211",
    "http://www.ncbi.nlm.nih.gov/pubmed/23634190",
    "http://www.ncbi.nlm.nih.gov/pubmed/25037206"
  ],
  "snippets": [
    {
      "text": "Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "These patients responded poorly to serotonin reuptake inhibitors, whereas treatment with opioid antagonist naltrexone resulted in the remission of PG.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The opioid antagonist naltrexone could be an effective option for the treatment of PG in PD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22426027",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "No improvement in the clinical features of either disorder was noted",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/152622",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Naltrexone as compared with placebo did not demonstrate any significant change in motor function in either group. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinsons disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969211",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:14330",
    "http://www.biosemantics.org/jochem#4249647"
  ]
}